Oxford Finance LLC

Founded 2002

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 111
Average round size
info
The average size of a deal this fund participated in
$26M
Portfolio companies 102
Rounds per year 5.84
Lead investments 28
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 59
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Pharmaceutical
Summary

In 2002 was created Oxford Finance LLC, which is appeared as Corporate Investor. The fund was located in North America if to be more exact in United States. The main department of described Corporate Investor is located in the Alexandria.

Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Avanir Pharmaceuticals, Auspex Pharmaceuticals, Ignyta.

The typical case for the fund is to invest in rounds with 1-2 participants. Despite the Oxford Finance LLC, startups are often financed by Versant Ventures, Silicon Valley Bank, Venrock. The meaningful sponsors for the fund in investment in the same round are MidCap Financial, Silicon Valley Bank, Square 1 Bank. In the next rounds fund is usually obtained by Vivo Capital, Versant Ventures, Accuitive Medical Ventures.

The fund is constantly included in 7-12 deals per year. The top activity for fund was in 2014. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2014. Considering the real fund results, this Corporate Investor is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Oxford Finance LLC performs on 22 percentage points more the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Oxford Finance LLC:
Typical Co-investors
Oxford Finance LLC is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Oxford Finance LLC:

Funds with similar focus

Funds from United States, Alexandria
Funds with similar focus located in United States, Alexandria:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Pinewood Studios Group United Kingdom, Buckingham
Tapit Partners United States, Healdsburg
Fleet Development Ventures United States, Boston
Chagral Invest -
Startup Autobahn Germany, Stuttgart
Siem Offshore Contractors Germany, Leer
Property Agent Japan, Tokyo
Kupanda Holdings -
Emerging Longevity Ventures -
DJR Advisors -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

4D Pharma

Biotechnology
Health Care
Pharmaceutical
n/a
$29M29 Jul 2021 United Kingdom, Aberdeen

Impel NeuroPharma

Delivery
Health Care
Medical Device
n/a
$50M07 Jul 2021 United States, Seattle

Kala Pharmaceuticals

Biotechnology
Medical
Pharmaceutical
n/a
$125M12 May 2021 United States, " United States"}

Mainstay Medical

Biotechnology
Emergency Medicine
Health Care
Medical
Medical Device
n/a
$50M20 Apr 2021 Ireland, Dublin

Immunocore

Biotechnology
Medical
Pharmaceutical
1
$100M11 Jan 2021 United Kingdom, Vale of White Horse

TMS NeuroHealth Centers Tysons Corner

Biotechnology
Health Care
Medical
Psychology
Therapeutics
n/a
$30M31 Dec 2020 United States, " United States"}

Nature’s Fynd

Agriculture
AgTech
Food and Beverage
Food Processing
Sustainability
n/a
$45M08 Dec 2020 United States, Chicago

RxSight

Biotechnology
Eyewear
Health Care
Medical Device
1
$60M01 Dec 2020 United States, " United States"}

SpendMend

Health Care
Information Technology
n/a
$55M08 Oct 2020 United States, Grand Rapids
News
Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticals

Oxford Finance LLC (“Oxford”), a leading specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide, has announced the closing of a $125 million senior secured term loan with Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye.
– Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the Kala’s marketing of its two approved ophthalmic products.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Oxford Finance LLC?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: